In an abnormal fibrinogen with severely impaired polymerization of fibrin monomers, we identified a methionine-to-threonine substitution at position 310 of the 'y chain. Furthermore, asparagine at position 308 was found to be N-glycosylated due to a newly formed consensus sequence, asparagine(308)-glycine(309)-threonine(310). The two structural defects in the mutant oy chain may well perturb the conformation required for fibrin monomer polymerization that is specifically assigned to the D domain of fibrinogen. This alteration also seems to affect the intermolecular y chain cross-linking of fibrin and fibrinogen, although the amine acceptor y glutamine-398 was found to function normally. These functional abnormalities may well be related to posttraumatic hemorrhage as observed in a 33-yr-old man with moderate hemorrhagic diathesis related to injuries since his early adolescence.
Introduction
The carboxy-terminal region of the fibrinogen y chain has been shown to participate in various functions of fibrinogen including fibrin polymerization (1) (2) (3) (4) (5) (6) (7) .
To form stable fibrin clots, several reactions take place sequentially or simultaneously. They include proteolytic cleavage of fibrinopeptides A and B by thrombin, polymerization of fibrin monomers to form fibrin gels, and intermolecular cross-linking mediated by activated blood coagulation factor XIII (Factor XIIIa) (4, 5) . Although polymerization and gelation of fibrin have been extensively studied (1) (2) (3) , little is known about the mechanisms involved in the reactions. For this purpose, congenital dysfibrinogens with well-elucidated structures may deserve careful study.
In this paper, we report a dysfibrinogen with two structural defects near the carboxy-terminal region of the y chain. The structure of the D domain may thus be critically perturbed so that polymerization of fibrin monomers and intermolecular cross-linking of the y chain can not proceed to form stable fibrin clots. The functional abnormalities are apparently associated with the clinical symptom of moderate bleeding as observed in the patient.
Methods
Hemostasis and blood coagulation studies. Blood was collected by venipuncture and immediately anticoagulated with 1/9 vol of 3.8% trisodium citrate. Plasma was harvested by centrifugation at 3,000 g for 30 min at 220C.
Routine hemostasis and blood coagulation were studied by standard methods (8, 9) or as described elsewhere (10, 1 1). Plasma fibrinogen was determined by various methods including the thrombin time method of Clauss (12-14).
Plasma proteins and enzymes. 200 ml of blood was also collected into a plastic bag containing 30 ml of acid-citrate-dextrose (ACD)' (Formula A; U. S. Pharmacopeia, Terumo Corporation, Tokyo, Japan) and plasma was separated by centrifugation at 3,000 g for 30 min at 4C.
Fibrinogen was purified from the ACD-plasma essentially as described (14-16). Portions of fibrinogen thus prepared were further treated with an anti-factor XIII (subunit A) MAb bound to protein A-Sepharose (Pharmacia Fine Chemicals, Uppsala, Sweden) to remove Factor XIII, a trace contaminant, and used for structure analysis. Plasminogen and Factor XIII were prepared from human plasma according to Deutsch and Mertz (17) and Lorand et al. (18) , respectively. Absorbance coefficients were 15.1 for fibrinogen (19) , 17.0 for plasminogen (20) , and 13.8 for Factor XIII (21) . Bovine thrombin was purified according to Lundblad (22) . Ancrod, a snake venom thrombin-like enzyme, was a kind gift from Dr. Minoru Fukuda, Mochida Pharmaceutical Co., Tokyo, Japan. Streptokinase was from Kabi Vitrum, Stockholm, Sweden, from which the albumin component had been removed with blue-Sepharose CL-6B. Glycopeptidase A and neuraminidase were from Seikagaku Kogyo, Tokyo, Japan.
Studies on purified fibrinogen. The determinations of thrombin and Ancrod times and the polymerization of fibrin monomers were carried out as previously described (14) (15) (16) 23) . Release of fibrinopeptides A and B was analyzed by reverse-phase HPLC (24) . The gross structure of fibrinogen, its plasmic degradation products and crosslinking profiles mediated by Factor XIIIa were analyzed by SDS-PAGE according to Laemmli (25) containing 5 mM CaCI2. At various incubation times, aliquots of 1.5 Mgg protein were removed and analyzed by SDS-PAGE. We also studied incorporation of monodansylcadaverine into fibrinogen by Factor XIIIa essentially as described (5, 29) .
Isolation of normal and abnormal fragment DI species from the plasmic digests ofpatient-derived ibrinogen. 40 Mg of the patient-derived fibrinogen was digested with plasmin (a mixture of 5.67 Committee on Thrombolytic Agents (CTA) units ofplasminogen and 6,000 U of streptokinase) and the digests were subjected to chromatofocusing chromatography to isolate fragment DI essentially as described (15 XII, and XIII, plasminogen, antithrombin III, and a2-plasmin inhibitor were all within normal ranges. These data appeared to be compatible with congenital dysfibrinogenemia.
Although only his brother was available and found to be unaffected, we tentatively designated this abnormal fibrinogen as "fibrinogen Asahi."
Studies on purifiedfibrinogen. As summarized in Table 1 , both the thrombin and Ancrod times were markedly prolonged regardless of the presence or absence of calcium ions. The lack of correction of thrombin clotting of fibrinogen by calcium ions seems to be rather unique as compared with most of the other abnormal fibrinogens reported heretofore (39) .
By SDS-PAGE after reduction, we noticed two bands for the y chain of the patient-derived fibrinogen, one with a normal molecular weight and the other with a higher molecular weight by -3,000, as indicated by "y-Asahi" in Fig. 1 (lanes  2, 4, and 6 ). Although the release of fibrinopeptides A and B was normal as evidenced by HPLC (figures not shown), polymerization of fibrin monomers was severely impaired in both the absence and presence of calcium ions as shown in Fig. 2 .
We then analyzed cross-linking profiles of fibrin mediated by Factor XIIIa. As shown in A and B in Fig. 3 , the abnormal impaired polymerization of fibrin monomers. Therefore, we examined the cross-linking profile of fibrinogen to minimize the effect of polymerization. Here again, the mutant y chain species was not cross-linked even after 24 h of incubation (profiles not shown). To see whether the cross-linking sites of the y-Asahi chain function normally, we examined the amine acceptor glutamine (Gln)-398 by monitoring the incorporation of monodansylcadaverine. Fluorescence was equally incorporated into both the normal and y-Asahi chains (profiles not shown), indicating that the amine acceptor of the mutant y chain functions normally. Isolation ofnormal and abnormalfragment DI species. As depicted in Fig. 4 , fragment DI derived from the patient's fibrinogen was eluted in two peaks: one eluted at the same pH range between 5.8 and 5.5 as normal fragment DI, and the other eluted at a slightly more acidic pH range between 5.5 and 4.8. The peak fractions were collected and combined as indicated by horizontal bars I and II. By SDS-PAGE, peak I was identical with normal fragment DI, but peak II was found to possess a 3-kD higher molecular weight y chain (inset in Fig. 4 and lanes 3 and 4 in A, Fig. 6 ). The peak I fraction prolonged the clotting time of normal fibrinogen dose dependently, namely, 11.6, 14.2, 16.8, 21.1, and 27.5 s at the fragment DI/fibrinogen molar ratios (DI/Fbg) of0, 1, 2, 3, and 4, respectively. On the contrary, the peak II fraction did not significantly affect it (11.6, 11.8, 12.4, 12.6, and 12.5 s at the corresponding D1/Fbg molar ratios). Likewise, the peak I fraction inhibited polymerization of normal fibrin monomers significantly, but the peak II fraction did not do so (profiles not shown). These data indicate that the polymerization site(s) specifically assigned to the D domain is functional in the peak I but dysfunctional in the peak II fractions.
Binding ofthe isolatedfragment D, species to insolubilized and thrombin-activated fibrinogen. We then examined the binding ability of the normal and abnormal fragment DI species to thrombin-activated fibrinogen insolubilized onto microtiter plates in the presence or absence of calcium ions. As depicted in Fig. 5 , the binding of abnormal fragment DI was significantly lower than that of normal fragment DI under comparable conditions. Although the binding of abnormal fragment Di was apparently increased in the presence of calcium ions, it was still evidently lower than that of normal fragment DI in the absence of calcium ions.
Carbohydrate staining ofthe mutant y chain. The finding that the y-Asahi chain and the y remnant of abnormal fragment DI were apparently larger than the normal counterparts prompted us to investigate whether the y chain itself was elongated in the D domain, or whether some extra substances were attached to a normal length polypeptide. We first examined possible extra glycosylation to the mutant -y chain by staining the polypeptide remnants of fragment DI with dansylhydrazine. As shown in Fig. 6 , the Sy-Asahi remnant of fragment DI was clearly stained for carbohydrate (lane 4 in B), whereas the normal y chain remnant that lacks carbohydrate was not stained as expected (lane 3 in B) . Furthermore, the -y-Asahi chain showed strongly positive staining for carbohydrate (lane 2 in B) as compared with the normal By and y chains (lanes I and 2 in B). A. SDS-PAGE (R) 1 chromatofocusing. 40 ,g of plasmic digests of the patient's fibrinogen was applied onto a polybuffer exchanger gel column (1.2 X 18 cm) and eluted with 350 ml of polybuffer, pH 4.7, followed by 100 ml of 0.025 M glycine-HCI, pH 2.5, containing 0.1 M NaCi, as indicated by vertical arrows A and B, respectively. The flow rate was 20 ml/h and 5-ml fractions were collected. (Inset) SDS-PAGE of peak I and peak II fractions after reduction. PAGE and Western blotting. We found that the molecular weight for the mutant y remnant was higher in fragments DI and D2, but not so in fragment D3 as compared with the corresponding normal y remnants (profiles not shown). This indicated that the carboxy-terminal peptide removed upon conversion of fragment D2 to fragment D3; i.e., the aberrant oY 303-356 residue peptide, is most probably glycosylated. We thus attempted to isolate the putative aberrant y 303-356 peptide by reverse-phase HPLC. As shown in Fig. 7 A, identified an aberrant peak PI' that was eluted earlier than its normal counterpart PI. These peptide peaks were reduced, S-carboxymethylated, and subjected to rechromatography, and an aberrant peptide PI'-2 was isolated (lower figure in B). A portion of this peptide was desialylated and then treated with glycopeptidase A. This peptide was designated as PI'-2G. As shown in Table II , PI'-2 was identified as the y 303-338 residue peptide on the basis of the known sequence for the y chain (2, 3, 40) , but a methionine (Met) at cycle 8 of this peptide was found to be replaced by a threonine (Thr). Furthermore, an asparagine (Asn) at cycle 6 identified in the normal peptide was not detectable in this aberrant peptide, suggesting that Asn-308 in the mutant y chain is linked to an oligosaccharide. Indeed, in PI'-2G, we identified an aspartic acid (Asp) at cycle 6, which was certainly derived from N-gly- cosylated Asn upon treatment with glycopeptidase A. We thus concluded that Met-3 10 is replaced by a Thr and consequently, Asn-308 is N-glycosylated because of a newly constructed consensus sequence of Asn(308)-glycine(Gly)(309)-Thr(310) in the mutant ly chain.
Analysis by HPLC ofoligosaccharides linked to y Asn-308 ofthe mutant y chain. The oligosaccharide was separated from the aberrant y 303-356 peptide and analyzed by HPLC. For comparison, the normal B,3 and -y chains and the B3 chain separated from the patient's fibrinogen (41) were also analyzed. Fig. 8 depicts the reverse-phase column elution profiles for the pyridylamino derivatives of oligosaccharides separated from the aberrant y 303-356 peptide (A), the normal y chain (B), the patient-derived B(3 chain (C), and the normal B,3 chain (D). There are no substantial differences among elution profiles for all the oligosaccharides. Among them, peak 5 was found to represent a biantennary oligosaccharide proposed for and D, the normal Bfl chain. (48) . Despite the two structural defects in or near the putative calcium binding site, the y 303-356 (3) or the y 311-336 residue segment (49) , the calcium binding ability seems to be well preserved based on the observed normal calcium effect on the protection against plasmic cleavage of the y remnant of abnormal fragment DI (Figs. 4 and 6 ).
Upon amino acid sequence analysis of the aberrant y 303-338 residue peptide PI'-2 by Edman degradation, the phenylthiohydantoin (PTH) derivative of an Asn was not detectable at cycle 6 of the aberrant peptide, suggesting that the Asn was glycosylated. Indeed, a PTH derivative of an Asp was recovered at cycle 6 as a product from the N-glycosylated Asn, when the peptide had been digested with glycopeptidase A that specifically hydrolyzes f3-aspartylglycosylamine linkages (36, 50, 51) . This extra glycosylation is certainly attributed to a newly constructed tripeptide sequence, Asn(308)-Gly(309)-Thr(3 10) because of a Met-3I0-to-Thr substitution. Such a mutation was formerly proposed for the mutant Bf3 chain of fibrinogen Pontoise (52), namely, a replacement of the B3 Ala-335 by a Thr and possible glycosylation at the Bf3 Asn-333 based on an amino acid analysis of an aberrant tryptic peptide.
However, no detailed data have so far been provided on the possible extra carbohydrate moiety in this abnormal molecule.
In this study, we provided evidence that the extra carbohy- drate moiety linked to Asn-308 of the mutant y-Asahi chain is identical to those linked to the normal B# (B# Asn-364) and y (,y Asn-52) chains (42) (Fig. 8) . The carbohydrate moiety was found to be composed of the major oligosaccharide with a biantennary structure (42) and two minor components lacking the ,3(1,4) galactose attached to the a(x1,3)-linked mannose or that attached to the a(1,6)-linked mannose (38) . The biantennary structure has also been reported for the oligosaccharides of the mutant y chain of fibrinogen Nagoya (53).
